Oxidative stress in polycystic ovary syndrome

Current Pharmaceutical Design

Volumn 22, Issue 18, 2016, Pages 2709-2722

  Papalou, Olga ^a   Victor, Victor M ^b   Diamanti Kandarakis, Evanthia ^a  

^a Athens Euroclinic   (Greece)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Advanced glycation end products; Oxidative stress; Polycystic ovary syndrome

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; FATTY ACID; FOLLITROPIN; FOLLITROPIN RECEPTOR; FREE RADICAL; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GONADORELIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL; INSULIN; INSULIN SENSITIZING AGENT; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; METFORMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENIUM; SUPEROXIDE DISMUTASE; THIOCTIC ACID; VITAMIN D; ZINC;

ABDOMINAL OBESITY; ARTICLE; DIET; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; METABOLISM; PATHOPHYSIOLOGY;

FEMALE; HUMANS; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME;

EID: 84974718856     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160216151852     Document Type: Article

References (187)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metabol 1999; 84: 4006-11.
2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-51.
3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Rev 2012; 33: 981-1030.
4. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol 2002; 174: 1-5.
5. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005; 11: 631-43.
6. de Melo AS, Dias SV, Cavalli Rde C, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction 2015; 150: R11-24.
7. Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des 2012; 18: 270-82.
8. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011; 95: 1048-58.
9. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006; 1092: 175-86.
10. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod update 2013; 19: 268-88.
11. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552: 335-44.
12. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015; 6: 456-80.
13. Li H, Horke S, Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014; 237: 208-19.
14. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: a review. Reprode Biol Endocrinol 2012; 10: 49.
15. Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome? Metabol: Clin Exp 2015; 64: 1564-73.
16. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
17. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metabol 2006; 91: 2100-4.
18. Welt CK, Duran JM. Genetics of polycystic ovary syndrome. Seminars Reprod Med 2014; 32: 177-82.
19. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Rev 2015; 36: 487-525.
20. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43: 55-9.
21. Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 2012; 44: 1020-5.
22. Lee H, Oh JY, Sung YA, et al. Genome-wide association study identified new susceptibility loci for polycystic ovary syndrome. Hum Reprod 2015; 30: 723-31.
23. Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6: 7502.
24. Saxena R, Georgopoulos NA, Braaten TJ, et al. Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance. Hum Reprod 2015; 30: 1454-9.
25. Dumesic DA, Goodarzi MO, Chazenbalk GD, Abbott DH. Intrauterine environment and polycystic ovary syndrome. Semin Reprod Med 2014; 32: 159-65.
26. Abbott DH, Bacha F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood. Fertil Steril 2013; 100: 2-11.
27. Rae M, Grace C, Hogg K, et al. The pancreas is altered by in utero androgen exposure: implications for clinical conditions such as polycystic ovary syndrome (PCOS). PloS One 2013; 8: e56263.
28. Soto N, Bazaes RA, Pena V, et al. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. J Clin Endocrinol Metabol 2003; 88: 3645-50.
29. Barra R, Cruz G, Mayerhofer A, Paredes A, Lara HE. Maternal sympathetic stress impairs follicular development and puberty of the offspring. Reproduction 2014; 148: 137-45.
30. Boutzios G, Livadas S, Piperi C, et al. Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. Fertil Steril 2013; 99: 943-50.
31. Nader S. Hyperandrogenism during puberty in the development of polycystic ovary syndrome. Fertil Steril 2013; 100: 39-42.
32. Dumesic DA, Richards JS. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril 2013; 100: 23-38.
33. Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003; 362: 1017-21.
34. Hoang YD, McTavish KJ, Chang RJ, Shimasaki S. Paracrine regulation of theca androgen production by granulosa cells in the ovary. Fertil Steril 2013; 100: 561-7.
35. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-32.
36. Rice S, Christoforidis N, Gadd C, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005; 20: 373-81.
37. Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome. PloS One 2013; 8: e80416.
38. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metabol 2001; 281: E392-9.
39. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007; 192: 585-94.
40. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015; 149: R219-27.
41. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009; 15: 297-307.
42. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metabol 2006; 91: 5022-28.
43. Manneras-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metabol 2011; 96: E304-11.
44. Chen CI, Hsu MI, Lin SH, Chang YC, Hsu CS, Tzeng CR. Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 264-8.
45. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metabol 2004; 89: 2548-56.
46. Papalou O, Livadas S, Karachalios A, et al. White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones 2015; 14: 91-100.
47. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metabol 2004; 89: 806-11.
48. Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metabol 2008; 294: E576-81.
49. Lambert EA, Teede H, Sari CI, et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clin Endocrinol 2015;
50. Kuppusamy S, Pal GK, Habeebullah S, Ananthanarayanan PH, Pal P. Association of sympathovagal imbalance with cardiovascular risks in patients with polycystic ovary syndrome. Endocrine Res 2015; 40: 37-43.
51. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target? Clin Endocrinol 2012; 77: 791-801.
52. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-5.
53. Pitocco D, Zaccardi F, Di Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. The review of diabetic studies: RDS 2010; 7: 15-25.
54. Bayir H. Reactive oxygen species. Crit Care Med 2005; 33: S498-501.
55. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7-15.
56. Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. Hum Reprod Update 1998; 4: 3-24.
57. Burton GJ, Jauniaux E. Oxidative stress. Best Practice Res Clin Obstet Gynaecol 2011; 25: 287-99.
58. Dixit VD, Parvizi N. Nitric oxide and the control of reproduction. Animal Reprod Sci 2001; 65: 1-16.
59. Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Eur J Obstet Gynecol, Reprod Biol 2015; 191: 15-22.
60. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289: H2649-56.
61. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015; 14: 6.
62. Grodnitskaya EE, Kurtser MA. Homocysteine metabolism in polycystic ovary syndrome. Gynecological Endocrinol 2012; 28: 186-9.
63. Caglar GS, Oztas E, Karadag D, Pabuccu R, Demirtas S. Ischemiamodified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. Fertil Steril 2011; 95: 310-3.
64. Yilmaz M, Biri A, Bukan N, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258-63.
65. Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009; 204: 509-14.
66. Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009; 88: 612-7.
67. Macut D, Simic T, Lissounov A, et al. Insulin resistance in nonobese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Exp Clin Endocrinol Diabetes 2011; 119: 451-55.
68. Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2012; 35: 317-21.
69. Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril 2009; 92: 1372-7.
70. Moti M, Amini L, Mirhoseini Ardakani SS, Kamalzadeh S, Masoomikarimi M, Jafarisani M. Oxidative stress and anti-oxidant defense system in Iranian women with polycystic ovary syndrome. Iranian J Reprod Med 2015; 13: 373-8.
71. Sova H, Morin-Papunen L, Puistola U, Karihtala P. Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndrome. Fertil Steril 2010; 94: 2670-3.
72. Sova H, Puistola U, Morin-Papunen L, Karihtala P. Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. Fertil Steril 2013; 99: 593-8.
73. Bayram F, Kocer D, Ozsan M, Muhtaroglu S. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol Endocrinol 2012; 28: 497-501.
74. Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2014; 30: 367-71.
75. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009; 87: 235-47.
76. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metabol 2012; 97: 2231-42.
77. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol 2008; 69: 634-41.
78. Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J Reprod Med 2013; 58: 107-14.
79. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008; 65: 233-9.
80. Marsillach J, Checa MA, Pedro-Botet J, Carreras R, Joven J, Camps J. Paraoxonase-1 in female infertility: a possible role against oxidative stress-induced inflammation. Fertil Steril 2010; 94: 1132-4.
81. Baskol G, Aygen E, Erdem F, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2012; 91: 326-30.
82. Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod 2008; 23: 1602-6.
83. Zhang J, Zhang Y, Liu H, et al. Antioxidant properties of highdensity lipoproteins are impaired in women with polycystic ovary syndrome. Fertil Steril 2015; 103: 1346-54.
84. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Invest 2001; 8: S40-42.
85. Bedaiwy MA, Elnashar SA, Goldberg JM, et al. Effect of follicular fluid oxidative stress parameters on intracytoplasmic sperm injection outcome. Gynecol Endocrinol 2012; 28: 51-5.
86. Pasqualotto EB, Agarwal A, Sharma RK, et al. Effect of oxidative stress in follicular fluid on the outcome of assisted reproductive procedures. Fertil Steril 2004; 81: 973-6.
87. Qiao J, Feng HL. Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 2011; 17: 17-33.
88. Ruder EH, Hartman TJ, Blumberg J, Goldman MB. Oxidative stress and antioxidants: exposure and impact on female fertility. Hum Reprod Update 2008; 14: 345-57.
89. Yildirim B, Demir S, Temur I, Erdemir R, Kaleli B. Lipid peroxidation in follicular fluid of women with polycystic ovary syndrome during assisted reproduction cycles. J Reprod Med 2007; 52: 722-6.
90. Chattopadhayay R, Ganesh A, Samanta J, Jana SK, Chakravarty BN, Chaudhury K. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecol Obstet Invest 2010; 69: 197-202.
91. Karuputhula NB, Chattopadhyay R, Chakravarty B, Chaudhury K. Oxidative status in granulosa cells of infertile women undergoing IVF. Syst Biol Reprod Med 2013; 59: 91-8.
92. Berker B, Kaya C, Aytac R, Satiroglu H. Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction. Hum Reprod 2009; 24: 2293-302.
93. Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril 2010; 93: 1864-9.
94. Meng Y, Qian Y, Gao L, Cai LB, Cui YG, Liu JY. Downregulated expression of peroxiredoxin 4 in granulosa cells from polycystic ovary syndrome. PloS One 2013; 8: e76460.
95. Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assisted Reproduc Genet 2014; 31: 1269-76.
96. Rezvanfar MA, Shojaei Saadi HA, Gooshe M, Abdolghaffari AH, Baeeri M, Abdollahi M. Ovarian aging-like phenotype in the hyperandrogenism-induced murine model of polycystic ovary. Oxidat Med Cell Longevity 2014; 2014: 948951.
97. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immunohistochemical localization of advanced glycation endproducts (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007; 127: 581-9.
98. Diamanti-Kandarakis E, Chatzigeorgiou A, Papageorgiou E, Koundouras D, Koutsilieris M. Advanced glycation end-products and insulin signaling in granulosa cells. Exp Biol Med 2015 May 7. pii: 1535370215584937. [Epub ahead of print].
99. Papachroni KK, Piperi C, Levidou G, et al. Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J Cell Mol Med 2010; 14: 2460-9.
100. Kandaraki E, Chatzigeorgiou A, Piperi C, et al. Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. Mol Med 2012; 18: 1183-9.
101. Diamanti-Kandarakis E, Piouka A, Livadas S, et al. Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160: 847-853.
102. Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PloS one 2010; 5: e11302.
103. Nasiri N, Moini A, Eftekhari-Yazdi P, et al. Abdominal obesity can induce both systemic and follicular fluid oxidative stress independent from polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2015; 184: 112-6.
104. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxidants Redox Signal 2005; 7: 1040-52.
105. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metabol 2006; 91: 336-40.
106. Gonzalez F, Sia CL, Shepard MK, Rote NS, Minium J. Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome. Hum Reprod 2012; 27: 3560-8.
107. Savic-Radojevic A, Bozic Antic I, Coric V, et al. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. Hormones 2015; 14: 101-8.
108. Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metabol 2012; 97: 2836-43.
109. Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metabol 2012; 302: E297-306.
110. Malin SK, Kirwan JP, Sia CL, Gonzalez F. Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic betacell dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metabol 2014; 99: 322-9.
111. Malin SK, Kirwan JP, Sia CL, Gonzalez F. Pancreatic beta-cell dysfunction in polycystic ovary syndrome: role of hyperglycemiainduced nuclear factor-kappaB activation and systemic inflammation. Am J Physiol Endocrinol Metabol 2015; 308: E770-7.
112. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Ann Rev Pathol 2007; 2: 31-56.
113. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diabetes Rep 2011; 11: 179-84.
114. Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril 2014; 102: 1167-74.
115. Groth SW. Adiponectin and polycystic ovary syndrome. Biol Res Nursing 2010; 12: 62-72.
116. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
117. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-5.
118. Kahler J, Ewert A, Weckmuller J, et al. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovas Pharmacol 2001; 38: 49-57.
119. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metabol 2001; 86: 4666-73.
120. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-9.
121. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-31.
122. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004; 150: 793-8.
123. Victor VM, Rocha M, Banuls C, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metabol 2011; 96: 3115-22.
124. Fortuno A, San Jose G, Moreno MU, Diez J, Zalba G. Oxidative stress and vascular remodelling. Exp Physiol 2005; 90: 457-62.
125. Christakou C, Economou F, Livadas S, et al. Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander? Hormones 2011; 10: 292-7.
126. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obesity 2007; 31 (Suppl 2): S8-13; discussion S31-12.
127. Marseglia L, Manti S, D'Angelo G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 2015; 16: 378-400.
128. Matsuzawa-Nagata N, Takamura T, Ando H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabol Clin Exp 2008; 57: 1071-7.
129. Yuzefovych LV, Musiyenko SI, Wilson GL, et al. Mitochondrial DNA damage and dysfunction, and oxidative stress are associated with endoplasmic reticulum stress, protein degradation and apoptosis in high fat diet-induced insulin resistance mice. PloS One 2013; 8: e54059.
130. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metabol 2003; 88: 4673-6.
131. Olusi SO. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obesity Relat Metabol Disord 2002; 26: 1159-64.
132. Roberts CK, Vaziri ND, Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation 2002; 106: 2530-2.
133. Mehrabani HH, Salehpour S, Amiri Z, et al. Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. J Am Coll Nutr 2012; 31: 117-25.
134. Asemi Z, Samimi M, Tabassi Z, et al. Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized clinical trial. Nutrition 2014; 30: 1287-93.
135. Razavi M, Jamilian M, Kashan ZF, et al. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome. Horm Metab Res 2016; 48(3): 185-90.
136. Jamilian M, Foroozanfard F, Bahmani F, et al. Effects of zinc supplementation on endocrine outcomes in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biol Trace Element Res 2016; 170(2): 271-8.
137. Foroozanfard F, Jamilian M, Bahmani F, et al. Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Clin Endocrinol 2015; 83(6): 888-94.
138. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
139. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005; 1: 93-106.
140. Palimeri S, Palioura E, Diamanti-Kandarakis E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes, Metab Syndr Obes Targets Ther 2015; 8: 415-426.
141. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
142. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99: 15596-601.
143. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino acids 2012; 42: 1151-61.
144. Falcone C, Bozzini S, Guasti L, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. ScientificWorld J 2013; 2013: 584504.
145. Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod 2014; 29: 135-45.
146. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med 2007; 85: 1413-20.
147. Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metabol Clin North Am 2013; 42: 697-719.
148. Cai W, Ramdas M, Zhu L, et al. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012; 109: 15888-93.
149. Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones 2014; 13: 65-73.
150. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabol Clin Exp 2007; 56: 129-34.
151. Spritzer PM, Motta AB, Sir-Petermann T, et al. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 2015; 40: 195-212.
152. Domecq JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metabol 2013; 98: 4655-4663.
153. Alessio HM. Exercise-induced oxidative stress. Med Sci Sports Exercise 1993; 25: 218-24.
154. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 2008; 88: 1243-76.
155. Covas MI, Elosua R, Fito M, et al. Relationship between physical activity and oxidative stress biomarkers in women. Med Sci Sports Exercise 2002; 34: 814-9.
156. Goto C, Nishioka K, Umemura T, et al. Acute moderate-intensity exercise induces vasodilation through an increase in nitric oxide bioavailiability in humans. Am J Hyperten 2007; 20: 825-30.
157. Elosua R, Molina L, Fito M, et al. Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women. Atherosclerosis 2003; 167: 327-34.
158. Laufs U, Wassmann S, Czech T, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vascr Biol 2005; 25: 809-814.
159. Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011: CD007506.
160. Orio F, Giallauria F, Palomba S, et al. Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clin Endocrinol 2008; 68: 976-81.
161. Sprung VS, Cuthbertson DJ, Pugh CJ, et al. Nitric oxide-mediated cutaneous microvascular function is impaired in polycystic ovary sydrome but can be improved by exercise training. J Physiol 2013; 591: 1475-87.
162. Giallauria F, Palomba S, Maresca L, et al. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin Endocrinol 2008; 69: 792-8.
163. Randeva HS, Lewandowski KC, Drzewoski J, et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2002; 87: 4496-501.
164. Palomba S, Santagni S, Falbo A, et al. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Women's Health 2015; 7: 745-63.
165. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2013; 98: 4565-92.
166. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) Society. J Clin Endocrinol Metabol 2010; 95: 2038-49.
167. Meyer ML, Malek AM, Wild RA, et al. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012; 18: 112-26.
168. Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2003; 88: 2562-8.
169. Brinkworth GD, Noakes M, Moran LJ, et al. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. BJOG 2006; 113: 1308-14.
170. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metabol 2015; 100: 911-9.
171. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine Rev 2012; 33: 812-41.
172. Moran LJ, Ko H, Misso M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Dietetics 2013; 113: 520-45.
173. Masharani U, Gjerde C, Evans JL, et al. Effects of controlledrelease alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 2010; 4: 359-364.
174. Dona G, Sabbadin C, Fiore C, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol 2012; 166: 703-10.
175. Banting LK, Gibson-Helm M, Polman R, et al. Physical activity and mental health in women with polycystic ovary syndrome. BMC Women's Health 2014; 14: 51.
176. Diamanti-Kandarakis E, Economou F, Palimeri S, et al. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 2010; 1205: 192-198.
177. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocrine Rev 2003; 24: 633-67.
178. Glintborg D, Altinok ML, Mumm H, et al. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metabol 2014; 99: 2584-91.
179. Yilmaz M, Bukan N, Ayvaz G, K et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005; 20: 3333-40.
180. Stabile G, Borrielli I, Artenisio AC, Bruno LM, et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolescent Gynecol 2014; 27: 177-82.
181. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011; 95: 203-9.
182. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2008; 93: 2670-8.
183. Jensterle Sever M, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 2014; 170: 451-9.
184. Sathyapalan T, Shepherd J, Coady AM, et al. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metabol 2012; 97: 3951-5.
185. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metabol 2013; 98: 4798-807.
186. Macut D, Bjekic-Macut J, Savic-Radojevic A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013; 40: 51-63.
187. Thakker D, Raval A, Patel I, et al. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int 2015; 2015: 817-49.